However, these studies have produced conflicting results, which indicate either a better survival upon TMX therapy of breast cancer patients carrying SULT1A1 allele encoding enzyme with low activity [9] or, in contrast, worse survival of such patients [10, 43], or no impact whatsoever [35]. This evidence concerns the gene SULT1A1 and breast carcinoma.